Your search returned 2 results.

Sort
Unhighlight Highlight
Select all Clear all
Select titles to:
Results
1.
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28344112
Year: 2017
Citation:
  • The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
DOI:
Add to cart
2.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27650977
Year: 2016
Citation:
  • Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
DOI:
Add to cart
Pages

Powered by Koha